The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Human Serum Albumin Market During 2026–2030?
The human serum albumin market has experienced significant growth in recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to factors such as the limited availability of recombinant hsa, the ongoing reliance on plasma-derived hsa, rising hospital and clinical demand, the increasing application in diagnostic and therapeutic fields, and the widespread adoption of standard injection solutions.
The human serum albumin market size is anticipated to demonstrate robust growth in the upcoming years. It is projected to expand to $8.16 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is attributable to the development of yeast, bacterial, and plant-based recombinant HSA, an increasing demand for fatty acid-free formulations, the broadening of drug delivery and nutrition enhancement applications, rising investment in research laboratories, and increased procurement by hospitals and blood banks. Significant trends expected in the forecast period include a growing demand for both plasma-derived and recombinant human serum albumin, an expanding utilization of HSA in volume expanders and drug delivery systems, the increasing adoption of lyophilized powder and injection solutions, the expansion of its uses in hospital and research laboratory applications, and a focus on fatty acid-free and specialty HSA preparations.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp
Which Factors Are Influencing The Growth Of The Human Serum Albumin Market?
The rising occurrence of liver conditions is anticipated to fuel the expansion of the human serum albumin market moving ahead. These diseases encompass various ailments that compromise liver performance, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases stems from the growing incidence of obesity, where surplus abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), resulting in fat buildup, inflammation, and potential organ failure. Human serum albumin aids in managing liver disease by re-establishing blood volume, diminishing fluid retention, safeguarding renal function, and enhancing results in complications like ascites and hepatorenal syndrome. As an illustration, a report released in December 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that premature fatalities attributed to alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the expanding occurrence of liver illnesses is stimulating the growth of the human serum albumin market.
How Is The Human Serum Albumin Market Categorized Across Its Segment Groups?
The human serum albumin market covered in this report is segmented –
1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks
Subsegments:
1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin
2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin
Which Trends Are Influencing Demand In The Human Serum Albumin Market?
Companies operating within the human serum albumin market are concentrating on developing innovative solutions, such as animal-free recombinant excipients, to boost product safety, scalability, and compliance with regulatory requirements in biomanufacturing applications. An animal-free recombinant excipient is an inactive substance, biologically engineered through recombinant DNA technology without any animal or human-derived components, thereby ensuring high purity and safety for pharmaceutical and biomanufacturing uses. As an example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, unveiled Optibumin 25, the first recombinant 25% human serum albumin specifically for closed-system biomanufacturing. This product is optimized for downstream processing, formulation, and cryopreservation workflows, and is currently supplied in 100 mL single-use bags. With its animal-origin-free and chemically defined makeup, it provides high purity, consistency, and reduced risks of contamination. It is GMP-ready, scalable for commercial production, and offers a stable, sterile solution that easily integrates into applications like viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.
Which Firms Are Influencing Competition In The Human Serum Albumin Market?
Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.
Get The Full Human Serum Albumin Market Report:
https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report
Which Region Has The Greatest Market Share In The Human Serum Albumin Market?
North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Serum Albumin Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report
Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company
Wall Decor Market Report 2026
https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report
Painting And Wall Covering Contractors Market Report 2026
Commercial Flooring Market Report 2026
https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model